Journal of Cataract & Refractive Surgery · 2002 · 20 citations · 15 references
PharmacyOphthalmologyPharmacotherapyOcular PharmacologyOphthalmic Drug DeliveryOphthalmic SurgeryOcular ImplantsOphthalmic FormulationsOphthalmic OintmentsOphthalmic SolutionsTopical Ocular Drug DeliveryTopical Ophthalmic MedicationsAnti-inflammatory Eye MedicationsAnti-inflammatory Ocular Drug EffectsAnti-inflammatory Ophthalmic OintmentsAnti-inflammatory Ophthalmic TherapyOphthalmic Drug SafetySerious Adverse EventsTopical Anesthetic AgentsTopical Ophthalmic Formulation Safety
PURPOSE: To explore the efficacy and safety of 2 concentrations (0.1% and 0.2%) of sodium naproxen ophthalmic solution in controlling ocular inflammation in patients having phacoemulsification and intraocular lens implantation. SETTING: Service d'Ophtalmologie La Pitie' and Centre Ophtalmologique, Paris, and Clinique Sourdille, Nantes, France; Department of Ophthalmology, University of Lausanne, Switzerland. METHODS: One hundred one patients were randomly treated with naproxen 0.1%, naproxen 0.2%, or diclofenac 0.1% 3 times a day for 30 days starting the day before surgery. Postsurgical ocular inflammation was measured after 1, 10, and 30 days using the Kowa FC-1000 laser flare-cell meter and a conventional slitlamp biomicroscope. Safety parameters were evaluated at the same visits. RESULTS: Naproxen 0.2% ophthalmic solution and diclofenac 0.01% were comparable in controlling postsurgical inflammation. The naproxen was well tolerated. No serious adverse events occurred during the study. CONCLUSIONS: These preliminary results suggest that naproxen ophthalmic solution may be effectively and safely used to control inflammation after uneventful phacoemulsification. Because of the limited number of patients, larger studies are needed to confirm these results.
15
Release of Prostaglandins in Ocular Inflammation in the Rabbit
K.E. Eakins, R.A.F. Whitelocke, E. S. Perkins et al. · Nature New Biology · 1972 · 146 citations
Comparison of ocular prostaglandin synthesis inhibitors.